Global equity funds draw second weekly inflow amid war de-escalation hopes


April 6 (Reuters) – Investors bought global equity funds worth a net $15.02 billion in the March 26-April 1 ‌period, logging a second straight week of inflows, on ‌hopes that the U.S.-Israeli war with Iran could soon de-escalate.

Global equity funds ​received inflows of roughly $40.14 billion for the prior week, LSEG Lipper data showed.

U.S. President Donald Trump, however, ratcheted up pressure on Iran on Sunday, threatening to target its power plants ‌and bridges on Tuesday ⁠if the strategic Strait of Hormuz is not reopened.

Investors bought a net $7.05 billion worth of ⁠U.S. equity funds in the most recent week, after buying roughly $36.95 billion a week ago. European and Asian funds also received ​net ​purchases of $3.25 billion and $2.96 billion, ​respectively.

However, they divested bond funds ‌worth a net $19.58 billion, turning weekly net sellers for the first time since December 31, 2025.

They pulled out of high-yield and euro-denominated bond funds worth a significant $5.1 billion and $3 billion, respectively.

In the money market segment, investors extended net selling ‌for a second successive week, withdrawing $16.93 ​billion.

Meanwhile, selling pressure eased in the ​gold and other ​precious metals commodity funds as investors added $78.33 million ‌to these funds in their ​first weekly net ​purchases since February 25.

Global emerging markets, however, remained out of favour for a fourth straight week as investors ​withdrew approximately $3.29 billion ‌from bond funds and $1.98 billion from equity funds, data ​for a combined 28,838 funds showed.

(Reporting by Gaurav ​Dogra; Editing by Janane Venkatraman)



Source link

  • Related Posts

    What we know about the search as Savannah Guthrie returns to “TODAY”

    Investigators continue to search for Nancy Guthrie, the 84-year-old mother of “TODAY” co-anchor Savannah Guthrie, whose disappearance has transfixed the nation. Subscribe to read this story ad-free Get unlimited access…

    Neurocrine to buy Soleno Therapeutics for $2.9 billion

    April 6 (Reuters) – Neurocrine Biosciences will acquire rare disease drugmaker ‌Soleno Therapeutics for $2.9 billion in ‌cash, the companies said on Monday, marking ​the neuroscience-focused drugmaker’s expansion into metabolic…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    What we know about the search as Savannah Guthrie returns to “TODAY”

    What we know about the search as Savannah Guthrie returns to “TODAY”

    Thailand PM calls for energy saving as Middle East conflict drives price surge | Thailand

    Thailand PM calls for energy saving as Middle East conflict drives price surge | Thailand

    Alberta snowpacks much deeper thanks to heavy snowfall

    Alberta snowpacks much deeper thanks to heavy snowfall

    “I Didn’t Want To Let Anyone Down” – Mario Galaxy Movie Composer Wrote Much Of The Score In Hospital

    “I Didn’t Want To Let Anyone Down” – Mario Galaxy Movie Composer Wrote Much Of The Score In Hospital

    Canada Gazette – Part I, February 17, 2024, volume 158, number 7

    Neurocrine to buy Soleno Therapeutics for $2.9 billion

    Neurocrine to buy Soleno Therapeutics for $2.9 billion